As coronavirus disease (COVID-19) is continuing to spread around the world, C3 inhibition by a C3-targeted drug candidate, AMY-101, was recently evaluated in small independent cohorts of severe COVID-19 patients, given that targeting complement represents one approach for improving COVID-19-mediated immunothrombosis [167,168]. Here, C3 is linked to COVID-19.